A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Inclusion Criteria: 1. Diagnosis of PNH confirmed by flow cytometry with clone size \> 10%. 2. Have not received complement inhibitor therapy; 3. LDH \> 1.5\*ULN at screening. 4. Hemoglobin level \< 10 g/dL at screening. Exclusion Criteria: 1. Known or suspected hereditary or acquired complement deficiency; 2. Patients with laboratory evidence of bone marrow failure (reticulocytes \<100x109/L; platelets \<30x109/L; neutrophils \<0.5x109/L); 3. Presence or suspicion of a systemic active bacterial, viral, or fungal infection (based on judgment of the investigator) within 2 weeks prior to the first dose of HRS-5965; 4. History of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.) 5. Positive of HIV, HBsAg or HCVAb.